VARUN SHARMA — MEDIA FACTS
Last reviewed: 8 September 2026

PUBLIC NAME
Varun Sharma

CURRENT ROLES
Founder, CEO & CTO, NEUVIOR
Product architect, PHARMORIS

BASE
United Kingdom

FOCUS
Medicines systems, responsible AI and accountable innovation

INNOVATION-SUPPORT RECORD
NEUVIOR has been selected for non-dilutive support for defined R&D project work. This record links only project-level information already in the public domain.
VIONIX ZERO — public Innovate UK project record
PHARMORIS — public Innovate UK project record
Boundary: Maximum award value, eligible project cost, company contribution and cash received are different facts. Award ceilings and eligible project costs are not cash received, revenue, customer adoption or outcomes.

SHORT BIOGRAPHY
Varun Sharma is the Glasgow-born founder, CEO and CTO of NEUVIOR and product architect of PHARMORIS. A British-Indian entrepreneur, he is building medicines intelligence while developing the VARUNÉ portfolio across biosystems, space systems, AI and robotics. VARUNÉ Labs is a predevelopment programme operated by NEUVIOR.

NAME NOTE
Use Varun Sharma in current coverage, titles and metadata. Earlier publisher bylines are mapped at https://www.byvarun.com/about/#evidence-index.

SELECTED PUBLICATION RECORD
Express Pharma — “From capacity to capability: Five proofs for India’s pharma future” (7 September 2026; contributed commentary by Varun Sharma)
https://www.expresspharma.in/from-capacity-to-capability-five-proofs-for-indias-pharma-future/
Financial Times — “Letter: The real test is whether invention leads to adoption” (31 July 2026; earlier publisher byline mapped on the evidence-indexed biography)
Pharmaceutical Technology — “Why the India-UK trade deal now needs a five-gate implementation ledger” (28 July 2026)
ETPharma — “India’s pharma quality reset will be won after the inspector leaves” (4 August 2026)
BusinessCloud — “Why neurodivergent founders can excel at building complex systems” (18 March 2026)
Full classified publication index: https://www.byvarun.com/press/

PUBLICATION BOUNDARY
Commentary, podcast appearances, published letters, independent reports and derivative follow-on publications are classified separately. Publication does not prove endorsement, deployment, customer adoption or commercial outcome.

PORTFOLIO
VARUNÉ Group is the founder-led portfolio brand, not an asserted legal parent or holding company.
VARUNÉ Space Systems: exploratory, precommercial space systems direction.
VARUNÉ Biosystems: proposed research across biological timing and chronobiology; ageing and longevity; repair, regeneration and rejuvenation; medicines, therapeutics and formulations; and skin, hair, skincare and aesthetics.
VARUNÉ Intelligence: exploratory AI and robotics for complex real-world problems.
VARUNÉ Labs: a predevelopment programme operated by NEUVIOR PHARMACEUTICALS LTD (SC857853), exploring medicines, formulations, generics, personal care, fragrance and longer-range manufacturing plans. No confirmed facilities or manufacturing capability is claimed.

VERIFIED PUBLIC RECORD
VARUNÉ SPACE SYSTEMS LTD (SC857817): https://find-and-update.company-information.service.gov.uk/company/SC857817
VARUNÉ BIOSYSTEMS LTD (16820832): https://find-and-update.company-information.service.gov.uk/company/16820832
VARUNÉ INTELLIGENCE LTD (SC857816): https://find-and-update.company-information.service.gov.uk/company/SC857816
NEUVIOR Pharmaceuticals Ltd: https://find-and-update.company-information.service.gov.uk/company/SC857853
PHARMORIS UKRI project: https://gtr.ukri.org/projects?ref=10173524
VIONIX ZERO UKRI project: https://gtr.ukri.org/projects?ref=10180575
Scottish Enterprise coverage: https://www.thebusinessdesk.com/scotland/news/4220-glasgow-pharmatech-start-up-backed-by-scottish-enterprise
NHS DSP Toolkit record: https://www.dsptoolkit.nhs.uk/OrganisationSearch/SP480
Current PHARMORIS status: https://www.neuvior.com/product-status

BOUNDARIES
PHARMORIS is under controlled, non-production development. It is not presented as deployed, clinically validated, NHS-backed or production-ready.
Future venture theses are labelled by their current stage and do not imply customers, facilities, partnerships, funding, missions or regulated activity.

MEDIA CONTACT
varun@neuvior.com